Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSD

Brief description of study

The purpose of this research study is to see the short-term and long-term effects of topiramate on alcohol dependence comorbid (co-occurring) with post-traumatic stress disorder (PTSD). To assess whether topiramate is a safe and feasible treatment for alcohol dependence comorbid with PTSD, the effects of topiramate and specific genes on alcohol dependence, measurements of brain responses to stimulation of specific brain areas, and comparisons of blood markers and brain markers to determine differences in blood markers/brain markers in those taking topiramate versus those taking placebo. The use of topiramate in this study is investigational because topiramate is not FDA-approved to treat alcohol dependence comorbid with PTSD.

Our study teams will respond to the messages between normal office hours of 9AM to 5PM Monday through Fridays, excluding holidays. If this is a medical or psychiatric emergency, please dial 911 or walk to the nearest emergency room.


Clinical Study Identifier: s18-01405
ClinicalTrials.gov Identifier: NCT03667846
Principal Investigator: Charles R. Marmar.
Other Investigators: Eugene M Laska, Michael P. Bogenschutz, Carole Siegel, Mu Xu, Esther Blessing.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.